Part 5 of 5 in our series: What Makes a Modern CRO?
Inside HiRO’s Global Growth Story
From dashboards to development strategy, where HiRO sees AI creating value and where human expertise still matters most.
Where Automation Is Already Working
AI and automation are showing up across HiRO’s operations in practical, unglamorous ways. Sponsors now access real-time study data through digital dashboards – graphs, tables, and visual summaries. Rather than waiting on periodic static reports. Automation is also assisting in medical writing and pharmacovigilance, helping generate draft clinical documents and process safety data more efficiently.
The goal in each case is narrow and specific: reduce the manual workload on routine tasks so teams can spend more time on interpretation, analysis, and decision-making. Over time, HiRO expects these individual tools to knit together into a more integrated, company-wide system rather than remaining a collection of point solutions.
A Simple Internal Test
What’s more interesting than the tools themselves is the philosophy behind where HiRO chooses to invest its own effort. The internal rule is straightforward: if a task can eventually be handled entirely by AI, it’s probably not where the organization should be focusing its energy. Instead, HiRO concentrates on the harder, less automatable problems, building trusted relationships with hospitals and investigators, navigating regulatory environments that shift by country and quarter, managing the inevitable unexpected challenges that arise mid-program, and operating through a geopolitical landscape that keeps changing shape.
That’s also where cell and gene therapy programs are pushing HiRO’s capabilities right now. These modalities require more specialized trial designs and greater operational precision, and the organization describes itself as learning alongside its clients as newer approaches, including gene editing, continue to emerge. Particularly in China, where regulatory development and hospital system readiness suggest the field could move quickly in the years ahead.
The Part That Doesn’t Show Up in a Dashboard
Ask Karen Chu, HiRO Founder and CEO, what keeps her motivated after building HiRO from scratch, and the answer isn’t strategic, it’s personal. She recalls a patient who returned to work just a week after receiving treatment through a clinical program, something that would have been unthinkable before. It’s a reminder of how far the field has come: new medicines increasingly aren’t just extending life by months, but delivering long-term improvement and, in some cases, genuine cures.
That progress sits alongside a lot of unfinished business. Friends and family still ask why certain diseases have no treatment, or why clinical trial participation remains so difficult to navigate, questions that are, in their own way, a reminder of how much work is still ahead.
The Message to Prospective Partners
THiRO was built around a specific insight: a biotech team can have a genuinely promising therapy and still struggle with fundraising, strategic direction, or the sheer complexity of global clinical development. Closing that gap is the job. HiRO works with both established organizations and smaller biotech teams, on the premise that some of the most innovative science comes from teams still building out their resources and infrastructure.
The feedback HiRO hears most often from clients isn’t about a specific technology or dashboard, it’s that the leadership team stays genuinely involved in every program, treating each asset with the same care they’d bring to their own. It comes down to one recurring question clients ask directly: “if this were your product, what would you do?” That’s the standard HiRO tries to hold itself to on every program it takes on.
